V
31.09
-0.26 (-0.83%)
| Penutupan Terdahulu | 31.35 |
| Buka | 31.47 |
| Jumlah Dagangan | 780,353 |
| Purata Dagangan (3B) | 916,803 |
| Modal Pasaran | 2,470,362,368 |
| Harga / Pendapatan (P/E TTM) | 37.91 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.47 |
| Harga / Jualan (P/S) | 5.26 |
| Harga / Buku (P/B) | 2.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 7.13% |
| Margin Operasi (TTM) | 7.03% |
| EPS Cair (TTM) | 0.420 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.23% |
| Nisbah Semasa (MRQ) | 5.10 |
| Aliran Tunai Operasi (OCF TTM) | 89.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 76.93 M |
| Pulangan Atas Aset (ROA TTM) | 1.94% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Veracyte, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.4
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.40 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.54% |
| % Dimiliki oleh Institusi | 107.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Needham, 54.39%) | Beli |
| Median | 42.50 (36.70%) | |
| Rendah | 37.00 (Morgan Stanley, 19.01%) | Jual |
| Purata | 42.50 (36.70%) | |
| Jumlah | 1 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 36.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 06 Mar 2026 | 37.00 (19.01%) | Jual | 33.85 |
| Needham | 26 Feb 2026 | 48.00 (54.39%) | Beli | 38.75 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |